<DOC>
	<DOC>NCT00272935</DOC>
	<brief_summary>This is a randomized, double-blind study to compare the efficacy and safety of daily doses of Cenestin 0.3 mg tablets to placebo in reducing the frequency and severity of moderate to severe hot flashes in postmenopausal women.</brief_summary>
	<brief_title>A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes</brief_title>
	<detailed_description>The overall study duration will be approximately 16 weeks. After a screening/baseline period of up to 4 weeks patients will be randomized to receive either placebo tablets or Cenestin 0.3mg tablets</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estrogens, conjugated synthetic A</mesh_term>
	<criteria>Naturally or surgically postmenopausal At least 12 months since last menses or 6 weeks past surgery Minimum of 7 daily or 50 weekly moderate to severe hot flashes Any contraindication to natural or synthetic estrogens</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>menopause</keyword>
	<keyword>vasomotor symptoms</keyword>
</DOC>